Here are 1-3 brief analogies for iSpecimen (ISPC):

• An eBay for human biospecimens.
• An Amazon for research samples and data.

• iSpecimen Marketplace Platform: A technology platform that allows researchers to search for, discover, and procure human biospecimens and associated de-identified clinical data from a global network of suppliers.
• Custom Biospecimen Acquisition Services: Services for obtaining precisely specified human biospecimens, often through prospective collections, tailored to researchers' unique project criteria.

iSpecimen (ISPC) operates primarily in a business-to-business (B2B) model, providing human biospecimens and related data to organizations engaged in scientific research and development. The company does not publicly disclose specific names of its individual major customers. According to its financial filings, iSpecimen typically serves a diverse customer base, with no single customer accounting for a significant portion (e.g., greater than 10%) of its total revenue, which is common for companies in this industry.

Instead, iSpecimen sells primarily to the following categories of companies:

• Pharmaceutical Companies: These companies utilize biospecimens for drug discovery, preclinical research, and understanding disease mechanisms to develop new therapeutic treatments.
• Biotechnology Companies: Similar to pharmaceutical companies, biotech firms leverage biospecimens for research into biological processes, product development, and innovation in health and medicine.
• Academic Research Institutions: Universities, medical schools, and non-profit research centers use iSpecimen's resources for basic science research, disease understanding, and translational studies.
• Diagnostic Companies: Firms developing new diagnostic tests and tools rely on biospecimens to validate assays, identify biomarkers, and improve disease detection methods.
• Contract Research Organizations (CROs): CROs, which provide outsourced research services to pharmaceutical, biotechnology, and medical device companies, often procure biospecimens through iSpecimen for their clients' studies.

Given the nature of iSpecimen's business and the typical lack of disclosure for individual major customers due to confidentiality and revenue diversification, it is not possible to list specific customer companies with their symbols.

Katharyn Field, Chief Executive Officer

Katharyn Field was appointed CEO, Secretary, and Treasurer of iSpecimen on November 7, 2025, after serving as President since February 2025. Her background includes extensive experience in strategy consulting and executive leadership, particularly within the cannabis industry. In 2014, she played a pivotal role in the procurement, build-out, and sale of one of Florida's original vertically integrated licensed medical marijuana treatment centers. She also operated a strategy consulting practice focused on cannabis and served as Executive Vice President of Corporate Development at MariMed from 2018 to 2019.

Yuying Liang, Chief Financial Officer

Yuying Liang was appointed Chief Financial Officer of iSpecimen on December 20, 2024. She brings extensive experience in corporate accounting and strategic guidance to her role.

Leslie Hoyt, Senior Vice President of Operations

Leslie Hoyt leads operations for iSpecimen and has over 30 years of experience as a Chief Operating Officer in healthcare. She focuses on operational efficiency, change management, and building strong relationships, excelling in start-up and high-growth environments. Prior to iSpecimen, she served as COO for biotech companies in the Boston area such as GNS (now Aitia), Olaris, and Naveris.

Annette Arnold, Vice President of Sales & Business Development

Annette Arnold is responsible for driving and managing all aspects of iSpecimen's sales and business development. She applies her strategic vision, negotiation skills, and facility management expertise, and plays a key role in developing the supply partner network. Arnold has over 20 years of experience in sales within the biospecimen market.

Carly Lejnieks, Vice President of Marketing

Carly Lejnieks leads marketing strategies, integrated programs, and high-growth initiatives for iSpecimen. She has over 20 years of experience in the Life Science industry, and before joining iSpecimen, she worked for more than a decade as a marketing consultant for clients in the healthcare and life science sectors.

The emergence and increasing adoption of microphysiological systems (e.g., organ-on-a-chip technology). These advanced in vitro models offer researchers human-relevant physiological environments for drug discovery, toxicology, and disease modeling. As these technologies mature and become more widely utilized, they could potentially reduce the demand for certain types of traditional primary human biospecimens by providing a viable, and in some cases, superior alternative for research previously reliant on such samples.

iSpecimen (NASDAQ: ISPC) operates an online marketplace that connects life science researchers with human biospecimens, such as blood, tissue, and cells, from healthcare organizations worldwide. Their main service is facilitating the procurement of these biospecimens for medical discovery and research.

The addressable markets for iSpecimen's services can be understood through the following market sizes:

• Global Human Biospecimens Market: This market was valued at approximately USD 12.42 billion in 2024 and is projected to reach around USD 26.45 billion by 2034.
• U.S. Human Biospecimens Market: The market size for human biospecimens in the U.S. was estimated at USD 3.48 billion in 2024 and is projected to grow to approximately USD 7.55 billion by 2034.
• Global Biospecimen Contract Research Services Market: iSpecimen is recognized as a key competitor in this market. It was valued at USD 5.0 billion in 2024 and is predicted to reach USD 17.7 billion by 2034.

iSpecimen Inc. (ISPC) is expected to drive future revenue growth over the next two to three years through several key strategic initiatives and operational improvements:

1. Expansion and Effectiveness of the Next Day Quote Program: The company's "Next Day Quote" program has demonstrated significant success, contributing to substantial revenue increases. This program is instrumental in improving efficiency, leading to higher specimen counts and an increased average selling price per specimen. In the second quarter of 2024, this program was a key factor in a 76% revenue increase, with 44% of quotes provided through it and 58% converting to purchase orders in the first half of 2024.
2. Strategic Expansion of the Global Biospecimen Supplier Network and Partnerships: iSpecimen is focused on enhancing its supplier quality and expanding its network. This includes adding new global biospecimen suppliers to its Marketplace platform, specifically bolstering capabilities in high-demand research areas such as oncology and cardiovascular diseases, and securing suppliers for emerging health concerns like human metapneumovirus (hMPV). This expansion aims to attract more researchers and increase the availability of diverse biospecimens.
3. Ongoing Investment in and Enhancement of the iSpecimen Marketplace Platform: To better serve researchers and capitalize on market opportunities, iSpecimen plans to invest approximately $1 million in technology upgrades to its Marketplace platform. These enhancements are aimed at improving customer engagement and the overall user experience, which is crucial for increasing platform utilization and transaction volumes.
4. Operational Efficiencies and Cost Management Initiatives: Although primarily focused on profitability, the company's commitment to operational efficiencies and cost reductions indirectly supports future revenue growth by strengthening its financial position. iSpecimen achieved a 59% reduction in cash burn from the first half of 2023 to the first half of 2024, freeing up resources that can be strategically reinvested into growth-generating activities.

Share Issuance

• iSpecimen completed an underwritten public offering in July 2025, raising approximately $4 million in gross proceeds by issuing 5,714,283 shares at $0.70 per share.
• In August 2025, the company closed a private placement of common stock and pre-funded warrants, generating approximately $1.75 million in gross proceeds from the issuance of 1,559,828 shares at $1.122 per share.
• Shareholders approved in October 2025 to increase the authorized capital stock from 250,000,000 to 1,000,000,000 shares, and also authorized potential future share issuances in private financings and through an equity line of credit.

Outbound Investments

• In August 2025, iSpecimen announced plans to establish a corporate treasury of up to $200 million built around the Solana cryptocurrency with BlockArrow, aiming for capital preservation, liquidity, and long-term growth.

Capital Expenditures

• Approximately $1 million from the proceeds of the July 2025 underwritten offering was allocated to an initial milestone payment for Sales Stack Solutions Corp.
• In August 2025, iSpecimen announced the completion of Milestone 1 in its digital transformation program with the Salestack Platform, involving the installation of the platform and provisioning of modern infrastructure.